Acousia Therapeutics GmbH is on a mission to address sensorineural hearing loss in both the pre-chemotherapy and chronic settings as it prepares to advance its first-in-class potassium channel-targeting candidate to a Phase II trial.
The German firm was founded in 2012 as a spin-off of research conducted by Hubert Löwenheim at the University of Tübingen aimed at making sensorineural hearing loss a treatable disorder....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?